Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT05105100
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Biopsy — PROCEDURE
    Tumor tissue collection
  • Biospecimen Collection — PROCEDURE
    Intravenously Blood draw

Study Details

This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor microenvironment (TME) can predict response and resistance to immunotherapy. These systemic tumor directed T cells can be defined by tumor/blood small conditional RNA (scRNA) using T cell receptor (TCR) as a barcode and can help predict response to Programmed death-1 (PD-1) therapy.

Key Dates

Start date
Oct 29, 2021
Status verified
Mar 2026
Primary completion
Sep 15, 2025
Completion
Sep 15, 2025

Study Design

Enrollment
25 participants (actual)

Arms

  • Arm: Participants with Melanoma
    Participants will undergo a pre-treatment tumor core biopsy and Peripheral blood mononuclear cell (PBMC) collection. Then, participants will be started on non-investigational pembrolizumab per standard of care and PBMCs will be collected every 3 weeks (1 cycle).

Primary Outcome Measure

Number of Genes Predictive of Response at Baseline [ Time Frame: At Baseline, 1 day ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143-

Find similar trials in San Francisco, CA

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
University of California, San Francisco· San Francisco, CA

Related Studies